Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
20.6M
-
Shares change
-
-5.29M
-
Total reported value, excl. options
-
$126M
-
Value change
-
-$36.2M
-
Put/Call ratio
-
1.52
-
Number of buys
-
29
-
Number of sells
-
-30
-
Price
-
$6.13
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q2 2018
85 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q2 2018.
AVADEL PHARMACEUTICALS - COM (AVDL) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.6M shares
.
Largest 10 shareholders include BRANDES INVESTMENT PARTNERS, LP (4.97M shares), Broadfin Capital, LLC (2.72M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.72M shares), ACADIAN ASSET MANAGEMENT LLC (1.33M shares), DEUTSCHE BANK AG\ (1.15M shares), RENAISSANCE TECHNOLOGIES LLC (1.05M shares), BROWN CAPITAL MANAGEMENT LLC (959K shares), Tekla Capital Management LLC (815K shares), BlackRock Inc. (488K shares), and MORGAN STANLEY (482K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.